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SUMMARY – Inflammatory bowel disease (IBD) patients with vitamin D deficiency show an 
increased risk of hospital admission, surgery, and loss of response to biologic therapy while high vita-
min D levels are identified as a protective factor. Our goal was to investigate the prevalence of un-
treated and undertreated vitamin D deficiency and factors associated with vitamin D deficiency. In 
this cross-sectional study, we measured serum vitamin D in a random sample of Caucasian IBD pa-
tients. Vitamin D deficiency was defined as <50 nmol/L and insufficiency as 50-75 nmol/L. Supple-
mentation was defined as taking 800-2000 IU vitamin D daily. Untreated patients were defined as not 
taking supplementation and undertreated group as receiving supplementation but showing vitamin D 
deficiency or insufficiency despite treatment. Our study included 185 IBD patients, i.e. 126 (68.1%) 
with Crohn’s disease (CD) and 59 (31.9%) with ulcerative colitis (UC). Overall, 108 (58.4%) patients 
had vitamin D deficiency and 60 (32.4%) patients vitamin D insufficiency. There were 16 (14.8%) and 
11 (18.3%) treated patients in vitamin D deficiency and vitamin D insufficiency group, respectively. 
The rate of untreated patients was 81.7% (n=49) in vitamin D deficiency group and 85.2% (n=92) in 
vitamin D insufficiency group. Tumor necrosis factor alpha inhibitors were associated with higher 
serum vitamin D levels in CD and UC, and ileal involvement, ileal and ileocolonic resection with 
lower levels. In conclusion, not only is vitamin D deficiency common in IBD patients but the propor-
tion of untreated and undertreated patients is considerably high. We suggest regular monitoring of 
vitamin D levels in IBD patients regardless of receiving vitamin D supplementation therapy.
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Introduction
Inflammatory bowel disease (IBD) is a relapsing-
remitting, immune-mediated chronic intestinal condi-
tion, which most commonly includes Crohn’s disease 
(CD) and ulcerative colitis (UC)1. The incidence and 
prevalence of IBD that is increasing worldwide points 
to the importance of investigating protective and risk 
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factors2,3. Epidemiological studies have so far identi-
fied a large number of environmental and genetic fac-
tors that can affect the risk of IBD, including vitamin 
D deficiency, lifestyle (smoking, urban living), medica-
tions (antibiotics, oral contraceptive therapy), surgical 
procedures (appendectomy, tonsillectomy), etc.4. In 
addition, high vitamin D levels are identified as a pro-
tective factor for CD, and possibly UC4,5. Vitamin D is 
a pleiotropic hormone lately recognized beyond its 
role in homeostasis of bone tissue and calcium. Vita-
min D can regulate immune system by affecting T 
lymphocytes, dendritic cells and macrophages, but also 
has a role of protecting and repairing intestinal muco-
sal barrier6-8. CD and UC can lead to vitamin D defi-
ciency due to a variety of reasons such as inflammatory 
activity, bowel resections, insufficient dietary intake, 
malabsorption, etc.9,10. There is evidence that indicates 
the existence of a north to south gradient, with the 
increasing incidence or prevalence of IBD patients in 
northern countries with less sun exposure and less 
naturally produced vitamin D as opposed to southern 
ones11-13. In addition, there is evidence that supports 
the increased risk of hospital admission, need for sur-
gical intervention and inadequate response to biologic 
therapy9,14,15. These findings indicate the necessity of 
regular monitoring and appropriate vitamin D supple-
mentation. Novel evidence, however, points to the im-
portance of the protective role of vitamin D in intesti-
nal epithelium, immunity and microbiota16.
The main objective of this study was to determine 
the prevalence of untreated and undertreated IBD pa-
tients among those with vitamin D deficiency and in-
sufficiency. Additionally, we identified factors associ-
ated with vitamin D deficiency.
Materials and Methods
Patient data
This was a cross-sectional study conducted at the 
Division of Gastroenterology and Hepatology, Depart-
ment of Internal Medicine, Zagreb University Hospital 
Centre. We recruited a random sample of Caucasian 
patients with IBD and measured serum vitamin D lev-
els. Measurements were done equally throughout the 
four seasons 2018-2019. Inclusion criteria were adult 
patients diagnosed with IBD, whereas exclusion criteria 
were systemic infection, bacterial, viral or parasitic in-
fection, diverticulitis, enterocolitis, ischemic colitis, dys-
function of the liver (cirrhosis, active hepatitis), primary 
sclerosing cholangitis, primary biliary cholangitis, 
chronic kidney disease, rheumatologic diseases (anky-
losing spondylitis, arthritis), malignant diseases, auto-
immune diseases, hematologic diseases, pregnancy, or 
refusal to participate. The study was approved by the 
ethics review board of the Zagreb University Hospital 
Centre. Each patient signed a written informed con-
sent. The study protocol was in line with ethical guide-
lines of the 1975 Declaration of Helsinki.
Anthropometric and demographic data
Data on anthropometric and demographic charac-
teristics, disease history and therapy were obtained 
from electronic medical records and questionnaires. 
Body height was measured in standing position with-
out shoes, and body mass without heavy clothing using 
Omron BF-511. Body mass index (BMI) was calcu-
lated as the ratio of weight in kilograms by square of 
height in meters (kg/m2).
Measurement of disease activity, localization  
and behavior
Inflammatory activity was defined using Harvey-
Bradshaw index (HBI) for CD and partial Mayo Score 
(PMS) for UC17,18. Patients were divided into groups 
depending on the HBI and PMS scores as follows: 
HBI <5 remission; HBI ≥5 active inflammation; PMS 
<2 remission; and PMS ≥2 active inflammation. Dis-
ease behavior and localization in CD and disease ex-
tent in UC patients were defined according to the 
Montreal classification and were obtained from elec-
tronic medical records19.
Disease specific medication
Disease specific medications that were currently 
used were included in the analysis. Medication use was 
defined as taking immunomodulators (azathioprine, 
methotrexate), tumor necrosis factor alpha (TNF-a) 
inhibitors (infliximab, adalimumab, golimumab), other 
biologic agents (vedolizumab, ustekinumab) and corti-
costeroids. Total biologic therapy was defined as taking 
TNF-a inhibitors, vedolizumab or ustekinumab.
Vitamin D measurements
Blood samples for vitamin D analysis were ob-
tained fasting in the morning on the day of entering 
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the study. Vitamin D deficiency and insufficiency were 
defined as levels of vitamin D lower than 50 nmol/L 
and 50-75 nmol/L, respectively. Vitamin D levels 
higher than or equal to 75 nmol/L were defined as 
‘normal’ or sufficiency20-22. Patients treated with sup-
plementation therapy were defined as taking 800-2000 
IU vitamin D daily. Patients with vitamin D deficiency 
or insufficiency and without vitamin D supplementa-
tion were considered untreated. Patients receiving vi-
tamin D supplementation that were still vitamin D 
deficient or insufficient were considered undertreated.
Statistical analysis
Percentage was used to report categorical variables, 
and mean with standard deviation or median with in-
terquartile range (25th and 75th percentiles) to report 
continuous variables. Distribution relationship be-
tween categorical variables was tested using χ2-test or 
Fisher exact test. Differences between two continuous 
variables were analyzed using two-way T-test for para-
metric or Mann-Whitney U-test for non-parametric 
analysis. To analyze more than two continuous vari-
ables, analysis of variance (ANOVA) with Tukey post-






Age (years) 37.3 (11.8) 36.9 (11) 38.1 (13.4)
Male gender, n (%) 106 (57.3) 75 (59.5) 31 (52.5)
Disease duration (years) 8 (25-14) 9 (4-15) 6 (3-11)
Body mass index (kg/m2) 24.3 (4.8) 24.2 (4.8) 24.4 (4.9)

































Biologic therapy (total), n (%) 115 (62.2) 85 (67.5) 30 (50.8)
Vitamin D supplementation, n (%) 33 (17.8) 15 (11.9) 18 (30.5)
Enteral nutrition, n (%) 21 (11.4) 14 (11.1) 7 (11.9)
Harvey-Bradshaw index 1 (0-3)
Partial Mayo Score 2 (0-4)
Active disease, n (%) 54 (29.2)  23 (18.3) 31 (52.5) 
Vitamin D level (nmol/L) 47.3 (20.6) 45.9 (22.3) 50.3 (16.2)
Categorical variables are shown as absolute number (percentage) and continuous variables as mean (standard 
deviation) or median (interquartile range); CD = Crohn’s disease; UC = ulcerative colitis; TNF-α = tumor necrosis 
factor alpha
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hoc analysis for parametric or Kruskal-Wallis with 
Mann-Whitney post hoc test for non-parametric 
analysis was used. Statistical significance was set at 
0.05 using IBM SPSS version 23.
Results
Characteristics of the study population
Our study included 185 IBD patients, i.e. 68.1% 
(n=126) CD and 31.9% (n=59) UC. Demographic 
characteristics are shown in Table 1. The mean age of 
the total study population was 37.3±11.8 years and 
57.3% (n=106) were male. The mean BMI of the study 
population was 24.3±4.8 kg/m2 (Table 1).
Demographic and clinical factors according to  
categories of vitamin D levels
Overall, 58.4% (n=108) of patients in our study 
were vitamin D deficient, and 32.4% (n=60) were vita-












Age (years) 37.3 (11.8) 41.2 (12.8)** 34.9 (10.5) 0.003*











Disease duration (years) 6 (1.5-10) 8 (3-15) 8 (4-13.75) 0.28
Body mass index (kg/m2) 23.3 (2.7) 26.6 (4.6)** 23.1 (4.7) <0.001*
Smoking, n (%) 2 (11.8) 7 (11.7) 25 (23.1) -
Localization CD, n
L1/L2/L3 2/2/9 11/7/17 15/9/54 0.30
Behavior CD, n
B1/B2/B3 6/5/2 17/9/8 21/34/23 0.14
Extension UC, n


































Biologic therapy (total), n (%) 10 (58.8) 41 (68.3) 64 (59.3) 0.49
Vitamin D supplementation, n (%) 6 (35.3) 11 (18.3) 16 (14.8) 0.12
Enteral nutrition, n (%) 6 (35.3) 4 (6.7) 11 (10.2) 0.004
Harvey-Bradshaw index 1 (0-2) 1 (0-4) 2 (0-3.25) 0.22
Partial Mayo Score 2.5 (0-5.75) 2 (0-4) 2 (0-3.25) 0.99
Active disease, n (%) 2 (11.8) 20 (33.3) 32 (29.6) 0.26
Categorical variables are shown as absolute number (percentage) and continuous variables as mean (standard deviation) or median (inter-
quartile range); *p<0.05, **highest value in post-hoc test; TNF-α = tumor necrosis factor alpha
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min D insufficient. Patients with vitamin D insuffi-
ciency were oldest and had highest BMI (41.2±12.8 
years and BMI 26.6±4.6 kg/m)2 (Table 2)
High prevalence of untreated and undertreated  
IBD patients
The rate of untreated patients was 82.2% (n=152), 
whereas the rate of undertreated patients was 14.6% 
(n=27). In the groups of patients with vitamin D insuf-
ficiency and deficiency, there was a large proportion of 
untreated patients (81.7% (n=49) and 85.2% (n=92), 
respectively), and a relatively large proportion of un-
dertreated patients (14.8% (n=16) in deficient and 
18.3% (n=11) in insufficient group) (Fig. 1).
Vitamin D supplementation increases  
25-OH vitamin D levels
Vitamin D supplementation was recorded in 14.8% 
(n=16) of IBD patients with vitamin D deficiency, 
18.3% (n=11) of those with vitamin D insufficiency 
and 35.3% (n=6) of patients with sufficient values. 
When comparing vitamin D levels in the CD and UC 
patients with and without supplementation, the differ-
ence between vitamin D levels was significant (p<0.013 
and p<0.05) (Figs. 2 and 3).
Vitamin D values do not depend on disease activity
Patients with CD and UC were analyzed separate-
ly. The average HBI and PMS scores in the study pop-
ulation of CD and UC patients were 1 (0-3) and 2 
(0-4), respectively. When comparing vitamin D levels 
in serum between CD and UC patients according to 
disease activity, there was no significant difference 
(p=0.095 and p=0.82, respectively) (Fig. 2).
Disease specific medication and vitamin D levels
Therapy with TNF-α inhibitors was associated 
with higher serum vitamin D levels in CD (39.3±28 
Fig. 1. Proportion of treated and untreated patients  
in different subgroups of serum vitamin D levels; X axis 
= vitamin D categories; Y axis = percentage of patients.
Fig. 2. Vitamin D levels according to different factors in patients  
with Crohn’s disease; Y axis = serum vitamin D levels; *p<0.05.
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vs. 28.9±23 mmol/L, p=0.049) and UC (56.3±20.3 vs. 
43.89±20.7 mmol/L, p=0.025) patients (Figs. 2 and 3). 
In contrast, therapy with immunomodulators and cor-
ticosteroids did not influence vitamin D levels in CD 
patients (p=0.67 and p=0.6, respectively) (Fig. 2). Sim-
ilarly, in UC there was no significant difference in vi-
tamin D levels regarding therapy with immunomodu-
lators (p=0.88) and corticosteroids either. However, 
corticosteroid therapy in UC had a trend towards 
lower vitamin D levels (42.2±19.6 vs. 53.7±21.2 
mmol/L, p=0.058 (Fig. 3).
Disease localization and extension
In the majority of CD patients included in the 
study, the disease involved both small and large bowel 
(63.5%, n=80). In CD patients with involvement of 
the ileum, vitamin D levels were significantly lower 
(33.8±17 vs. 48±26 mmol/L, p=0.041) (Fig. 2). In-
volvement of other parts of the intestine did not sig-
nificantly affect serum vitamin D levels. The extension 
of UC (proctitis, left side, pancolitis) showed no sig-
nificant difference in serum vitamin D levels (p=0.60) 
(Fig. 3).
Vitamin D values after surgical resections
We found significant differences in vitamin D levels 
between patients having undergone ileal and ilecolonic 
resection (26.3±20 vs. 40.4±28 mmol/L, p=0.008 and 
26.1±11 vs. 38.7±18, p=0.034, respectively) (Fig. 2).
Discussion
Recent studies have demonstrated that decreased 
levels of vitamin D in serum are a common finding 
among patients with CD and UC1. However, there are 
not enough data analyzing the proportion of untreated 
and undertreated IBD patients. More than half of the 
patients (58.4%) in our study population had vitamin 
D deficiency, and one-third of patients (32.4%) had 
vitamin D insufficiency. This is in line with other simi-
lar studies, which report high proportion of patients 
who were vitamin D deficient or insufficient23-26. In 
addition, the average BMI of our cohort was in the 
normal range, so the patients were not malnourished, 
which could also be a reason for low vitamin D levels. 
In a retrospective study by Ulitsky et al. on 504 IBD 
patients, of which 80% had been diagnosed with CD, 
49.8% were vitamin D deficient23. Analysis of vitamin 
D deficiency in an epidemiological collaboration 
amongst centers across Europe (Epi-IBD study) in-
cluding a cohort of 238 patients revealed a prevalence 
of vitamin D deficiency of 65.4% in CD and 53.7% in 
UC, and vitamin D insufficiency of 17.3% in CD and 
22.3% in UC25. Zullow et al. found the prevalence of 
Fig. 3. Vitamin D levels according to different factors in ulcerative colitis;  
Y axis = serum vitamin D levels; *p<0.05.
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vitamin D deficiency of 38.8% and vitamin D insuffi-
ciency of 28.6%24. Finally, Zator et al. report on 67% of 
patients with vitamin D levels lower than 30 ng/mL 
(75 nmol/L)26.
Along with the fact that vitamin D deficiency is 
common among IBD patients, the most significant 
finding in our study was the high proportion of un-
treated and undertreated patients. There were 81.7% of 
untreated patients in vitamin D insufficiency group 
and 85.2% in vitamin D deficiency group. In addition, 
there were 14.8% of undertreated patients in vitamin 
D deficiency group and 18.3% of undertreated patients 
in vitamin D insufficiency group. These patients were 
vitamin D treated but did not achieve sufficient vita-
min D levels. This clearly points to the importance of 
regular vitamin D level monitoring in patients on sup-
plementation therapy, and even to the need of substi-
tution with higher vitamin D dosages in a minor pro-
portion of patients. The ECCO and ESGAR guide-
lines suggest that initial laboratory investigations in 
IBD patients should include vitamin D, alongside 
with other routine parameters. In addition, serum vita-
min D levels should be measured in symptomatic IBD 
patients before and after treatment27,28. The ESPEN 
guidelines for clinical nutrition in IBD recommend 
monitoring of serum vitamin D and serum calcium in 
active and steroid-treated patients. If required, supple-
mentation should be given to help in osteopenia or 
osteoporosis prevention28,29. It is suggested that IBD 
patients should be regularly screened and appropri-
ately corrected not just for vitamin D deficiency but 
also for other micronutrient deficiencies27. These find-
ings suggest that more emphasis should be placed on 
detection and adequate treatment of low vitamin D 
levels.
Our study did not show any association of disease 
activity with serum vitamin D levels either in CD or 
UC patients. Several studies have reported association 
between inflammatory activity and vitamin D23,30-32. 
Meckel et al. showed association of vitamin D defi-
ciency with mucosal inflammation and disease activity 
in UC patients30. In addition, clinical and biochemical 
disease activity has also been reported as a factor as-
sociated with vitamin D deficiency25,31. However, in a 
retrospective study in a single northern German IBD 
cohort, patients were stratified according to clinical 
disease activity into highly active (HBI >9 or Simple 
Clinical Colitis Activity Index (SCCAI) >6) and those 
in remission (HBI 0-3 or SCCAI 0-2). Significantly 
lower vitamin D levels were found in UC group with 
highly active disease, which was not the case for CD9. 
Furthermore, in our study, patients with involvement 
of ileum had lower vitamin D levels, which was also 
the case in patients with ileal and ileocolonic resection. 
Similar findings were observed in the study by Shäffler 
et al., where they found a correlation between CD lo-
cated in small bowel and lower vitamin D levels, and 
resection of small bowel and lower vitamin D levels9. 
Disease activity, localization and surgical resections 
can cause vitamin D malabsorption through several 
different mechanisms. Factors that can lead to de-
creased absorptive surface are the site of inflammation, 
affection of small bowel (as in ileal and ileocolonic 
forms of CD), or surgical resections. Active disease can 
additionally lead to decreased food intake due to an-
orexia, restricted diets, abdominal pain, nausea, vomit-
ing, etc.33. In conclusion, according to current findings, 
it seems that the disease activity has an effect on vita-
min D levels although such analysis in our cohort of 
patients did not show any significance. Clinical disease 
activity has its known shortcomings, since there is 
poor correlation between clinical and endoscopic dis-
ease activity. Therefore, endoscopy as the gold standard 
would be better approach for assessment of disease ac-
tivity, also taking into account the effect of continuous 
inflammatory activity, which was not assessed in the 
above-mentioned studies.
In our study, vitamin D supplementation was re-
corded in 17.8% of IBD patients, 35.3% of patients 
with vitamin D sufficiency and 14.8% of IBD patients 
with vitamin D deficiency. As expected, the difference 
between vitamin D levels was higher in CD and UC 
patients who were taking vitamin D supplementation 
therapy. Also, patients with vitamin D sufficiency had 
the highest percentage of enteral nutrition supplemen-
tation. The Epi-IBD study indicated improvement of 
vitamin D levels owing to successful disease control 
rather than supplementation therapy25. If there is in-
flammation at the site of vitamin D absorption, con-
trol of inflammation could improve vitamin D absorp-
tion. However, vitamin D substitution therapy can be 
beneficial even in active disease. Even though there is 
active inflammation, certain part of the small bowel 
with functional absorptive surface can be intact since 
the inflammation in CD is not continuous, and in-
flammation in UC does not affect small bowel. Further 
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studies are needed to address vitamin D supplementa-
tion therapy in patients with active or inactive disease.
Our results showed an association between the ad-
ministration of TNF-α inhibitors with higher vitamin 
D levels in IBD patients, which is in line with the 
study by Schäffler et al.9. This study pointed out that 
patients treated with TNF-α inhibitors could have 
better disease control9. On the other hand, biologic 
treatment could be a surrogate marker of a more com-
plicated disease or disease that is uncontrollable, has 
longer disease duration, more bowel resections, etc. In-
teresting interaction of vitamin D levels and TNF-α 
inhibitors has been shown in several studies. Zator 
et al. conclude that patients with vitamin D insuffi-
ciency are prone to earlier discontinuation of anti-
TNF-α therapy as compared to patients with sufficient 
vitamin D levels in serum before starting biologic 
therapy26. In addition, there is evidence that vitamin D 
levels might be associated with the initial response to 
TNF-α inhibitors. Winter et al. showed that patients 
with low vitamin D levels before starting TNF-α 
treatment had lower odds for remission after 3 
months32.
There were several limitations to our study. The study 
was conducted at a single center with a relatively small 
patient sample. Since it was a cross-sectional design, our 
data cannot be used to analyze behavior over a period of 
disease duration and do not help determine the cause 
and effect of vitamin D deficiency in IBD. Also, we used 
clinical indices of disease activity, which correlate poorly 
with endoscopic disease activity indices.
In conclusion, not only is vitamin D deficiency 
common in IBD patients but the proportion of un-
treated and undertreated patients is also considerably 
high. This problem has not been emphasized in similar 
studies so far. Our suggestion is to monitor vitamin D 
levels in IBD patients regularly, regardless of receiving 
vitamin D supplementation, and to adjust vitamin D 
supplementation therapy. Additional studies are need-
ed to explore the possible impact of vitamin D in IBD 
pathogenesis given the consistent reports of low levels 
in this patient population.
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Sažetak
VISOKA UČESTALOST NELIJEČENE I NEDOVOLJNO LIJEČENE DEFICIJENCIJE  
I INSUFICIJENCIJE VITAMINA D U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA
V. Domislović, D. Vranešić Bender, A. Barišić, M. Brinar, D. Ljubas Kelečić, C. Rotim, M. Novosel, M. Matašin i Ž. Krznarić
Bolesnici s upalnim bolestima crijeva (inflammatory bowel disease, IBD) i manjkom vitamina D su pod povećanim rizikom 
hospitalizacije, operacije i gubitka odgovora na biološku terapiju, dok visoke serumske razine vitamina D predstavljaju zaštit-
ni čimbenik. Cilj ove studije bio je istražiti učestalost neliječenih i nedovoljno liječenih bolesnika s IBD i manjkom vitamina 
D te čimbenike rizika. U ovoj presječnoj studiji mjerene su serumske razine vitamina D u slučajnom uzorku bolesnika s IBD 
bijele rase. Deficijencija je definirana kao razine <50 nmol/L, a insuficijencija kao 50-75 nmol/L. Nadoknada vitamina D je 
definirana kao uzimanje 800-2000 IJ vitamina D na dan. Neliječeni bolesnici su oni bez nadoknade, a nedovoljno liječeni oni 
s deficijencijom ili insuficijencijom usprkos nadoknadi. Uključeno je ukupno 185 bolesnika s IBD, tj. 126 (68,1%) s Crohno-
vom bolešću i 59 (31,9%) s ulceroznim kolitisom. Ukupno je 108 (58,4%) bolesnika imalo deficijenciju, a 60 (32,4%) insufi-
cijenciju. Udio liječenih bolesnika s deficijencijom i insuficijencijom vitamina D iznosio je 14,8% (n=16) i 18,3% (n=11). 
Udio neliječenih s deficijencijom iznosio je 81,7% (n=49), a s insuficijencijom 85,2% (n=92). Terapija inhibitorima faktora 
tumorske nekroze alfa bila je povezana s višim razinama vitamina D. Niže razine vitamina D su zabilježene kod bolesnika s 
upalom u području ileuma i resekcijom ileuma ili ileokolona. U zaključku, niske serumske razine vitamina D su česta pojava 
kod bolesnika s IBD, a dodatno je udio neliječenih i nedovoljno liječenih također visok. Naša preporuka je kontinuirano 
praćenje razina vitamina D u serumu svih bolesnika s IBD uključujući i one na nadoknadi vitaminom D.
Ključne riječi: Upalne bolesti crijeva; Vitamin D, nedostatak; Crohnova bolest; Kolitis, ulcerozni
